ArchiveApril 2016

ClinicSpeak & NeuroSpeak: sequencing DMTs switching from natalizumab to alemtuzumab

Can you switch from natalizumab to alemtuzumab safely? #ClinicSpeak #Neurospeak #MSBlog “Finally, our algorithm for switching patients at high-risk of PML to other DMTs, in particular alemtuzumab, is in print. We originally published this algorithm on the blog way back in 2014 so why publish it in a journal now? Firstly, it is always good practice to get your work peer-reviewed and secondly...

EMA Panel Backs Daclizumab (Zinbryta) for Multiple Sclerosis

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for daclizumab (Zinbryta, Biogen Idec) for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Daclizumab is given by self-administered subcutaneous injection once a month. The humanized monoclonal antibody selectively binds to the...

What Does DrK think….Practice what you Preach!

Yesterday’s drug delivery, giving six people options where there maybe none…and saving the NHS up to £600,000.                   Can’t wait for the EMA…Cladribine Ready to Go  For those Health Care professionals and People with MS who may be interested.  We have updated our Information concerning off-label...

ClinicSpeak: suicide in Swedish MSers

Are you depressed? Please download the Beck Depression Inventory and assess yourself. #ClinicSpeak #MSBlog #MSResearch “The article below complements my post yesterday on loneliness and social isolation; it confirms that pwMS are at increased risk of both attempted suicide and completed suicide. Men are more successful at committing suicide than women. These are rather depressing figures...

Competition for Canbex

As you may know we are trying to develop a treatment for spasticity. Baclofen is the usual go to drug, but it is not without its problems. One is the Zombie effect because it is very sedating because it is sedative, because it inhibits nerve function making muscle weakness and having cognitive effects.  It also has a low binding affinity for its target the GABA B receptor. So you need high...

ClinicSpeak: calling on researchers to take on social isolation

Are you lonely and socially isolated? What can we do about it? #ClinicSpeak #MSBlog #MSResearch “If you have MS and are disabled there is a reasonable chance that you have become unemployed, split from your partner and have noticed your social group shrinking. In short you may be lonely and socially isolated. Social isolation is a big problem in chronic diseases, in particular multiple...

Alemtuzumab 10 years on

P2.086 – Incidence and Timing of Thyroid Adverse Events in Patients with RRMS Treated with Alemtuzumab through 5 Years of the CARE-MS Studies P.A senior et al. OBJECTIVE: To summarize 5-year incidence and timing of thyroid adverse events following alemtuzumab treatment in the ongoing CARE-MS extension study. BACKGROUND: In the phase 3 CARE-MS studies, patients with active relapsing...

ClinicSpeak & BrainHealth: are you up for routine cognitive testing?

Can we afford not to screen MSers for cognitive impairment? Have your say. #ClinicSpeak #BrainHealth #MSBlog “You are all aware that I ran a longish social media campaign to get MS rebranded a preventable dementia. My motivation was to get regulators to realise that early disability in MS is driven by cognitive impairment that occurs long before physical disability is noted. The hope...

ClinicSpeak & BrainHealth: wellness

What does wellness mean to you? #AAN2016 #BrainHealth #MSBlog “A key theme of the AAN 2016 was brain health and wellness. What does wellness mean to you? Can we define wellness and make it a therapeutic target in MS?” “We at Barts-MS continue to promote the holistic management of MS and brain health is simply one way of framing this strategy in relation to MS. However, wellness...

Translate

Categories

Recent Posts

Recent Comments

Archives